Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel
Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel
Recruiting · NCT05582538 · Registry updated 2025-08-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2025-08-24 | NCT05582538 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| IFOM ETS - The AIRC Institute of Molecular Oncology | 6 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| ASST Papa Giovanni XXIII | Bergamo | Italy | 21 |
| Azienda Ospedaliero Universitaria Maggiore della Carità | Novara | Italy | 1 |
| Azienda U.S.L. - IRCCS di Reggio Emilia | Reggio Emilia | Italy | 2 |
| IRCCS Istituto Nazionale Tumori "Fondazione Giovanni Pascale" | Naples | Italy | 3 |
| Istituto Nazionale dei Tumori IRCCS | Milan | Italy | 1 |
| Istituto Oncologico Veneto IRCCS | Padova | Italy | 8 |